Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology
Venous thromboembolism (VTE) is the third most common cause of death worldwide. The
incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person …
incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person …
Cancer-associated venous thromboembolism
Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …
events) is highly consequential for patients with cancer and is associated with worsened …
Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …
represents a major cause of morbidity and mortality in patients with cancer. Arterial …
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …
emergence of antibody-based immunotherapies that modulate immune responses against …
Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems
PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …
Hematologic complications of immune checkpoint inhibitors
Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune
cells to kill malignant cells. There are currently 7 medications that have been approved by …
cells to kill malignant cells. There are currently 7 medications that have been approved by …
Prevention of venous thromboembolism in patients with cancer
Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients
with cancer. Venous thromboembolism, which includes both deep vein thrombosis and …
with cancer. Venous thromboembolism, which includes both deep vein thrombosis and …
Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer
Background Venous thromboembolism (VTE) is a significant cause of morbidity and
mortality in patients with lung cancer. Systemic therapies, such as chemotherapy (chemo) …
mortality in patients with lung cancer. Systemic therapies, such as chemotherapy (chemo) …
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: a retrospective multicentric cohort study
Abstract Objectives Venous thrombotic events (VTEs) are a frequent complication of non-
small cell lung cancer (NSCLC) and are associated with increased morbidity. Immune …
small cell lung cancer (NSCLC) and are associated with increased morbidity. Immune …
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies
Patients with cancer have an increased risk of venous-and arterial thromboembolism
(VTE/ATE). Anti-cancer treatments including surgery, radiotherapy, and certain …
(VTE/ATE). Anti-cancer treatments including surgery, radiotherapy, and certain …